Skip to main content
MedPathMedPath Home
Clinical Trials/JPRN-UMIN000008055
JPRN-UMIN000008055
Completed
Phase 3

Sub-study on genetic markers responsible to effects of HMG-CoA reductase inhibitor preventing recurrence of stroke - J-STARS Genomics

Department of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences0 sites1,000 target enrollmentJune 1, 2012
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsIschemic stroke

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Ischemic stroke
Sponsor
Department of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences
Enrollment
1000
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 1, 2012
End Date
October 31, 2013
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Department of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
A research that investigates the genetic factors for the idiopathic pulmonary pneumonias (IIPs) with the subjects that have been enrolled in the multi-institutional observational study for the IIPs, NEJ030.Idiopathic pulmonary pneumonia
JPRN-UMIN000032117Jichi Medical University400
Recruiting
Not Applicable
A two parts, biomarker study to identify genetic aberrations predictive for response on Everolimus in solid tumors without regular treatment options (CPCT*03)regular therapy refractory cancer10027655
NL-OMON40040Antoni van Leeuwenhoek Ziekenhuis80
Active, not recruiting
Phase 1
Biomarkers of Response to Pembrolizumab Combined with Chemotherapy in Non-Small Cell Lung Cancer (Keynote-782)
EUCTR2018-002598-22-HUMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.100
Active, not recruiting
Phase 1
Biomarkers of Response to Pembrolizumab Combined with Chemotherapy in Non-Small Cell Lung Cancer (Keynote-782)
EUCTR2018-002598-22-ESMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.100
Not yet recruiting
Not Applicable
Heritability in Oropharynx CancerHealth Condition 1: C109- Malignant neoplasm of oropharynx,unspecified
CTRI/2019/07/020299Department of Health Research